Earnings call transcript: Stepan Q2 2025 results miss forecasts, shares dip

Stepan Company reported its Q2 2025 earnings, revealing an earnings per share (EPS) of $0.52, falling short of the forecasted $0.90. The revenue for the quarter reached $594.69 million, slightly below the expected $598.25 million. The stock reacted negatively to these results, with shares dropping 8.8% to $55.24 in pre-market trading. According to InvestingPro data, the company trades at a PEG ratio of 0.47, suggesting potential value despite the earnings miss. InvestingPro subscribers have access to 8 additional key insights about Stepan’s valuation and growth prospects.

Key Takeaways

• Stepan’s EPS of $0.52 missed the forecast by a significant margin.
• Revenue came in slightly below expectations at $594.69 million.
• The stock price fell by 8.8% following the earnings announcement.
• New product innovations and site expansions are underway.
• The company remains optimistic about full-year growth despite challenges.

Company Performance

Stepan Company experienced a mixed performance in Q2 2025. While the adjusted net income increased by 27% year-over-year to $12 million, and adjusted EBITDA rose by 8% to $51.4 million, the earnings per share did not meet market expectations. The company is navigating a challenging macroeconomic environment with high interest rates and fluctuating demand in various sectors.

Financial Highlights

• Revenue: $594.69 million, slightly below forecasts.
• Earnings per share: $0.52, compared to a forecast of $0.90.
• Adjusted net income: $12 million, up 27% year-over-year.
• Adjusted EBITDA: $51.4 million, up 8% year-over-year.

Earnings vs. Forecast

Stepan’s EPS of $0.52 represents a 42.22% miss from the forecasted $0.90. The revenue shortfall was modest at 0.6%, with actual revenue at $594.69 million against a forecast of $598.25 million. This significant EPS miss contrasts with the company’s historical trend of meeting or exceeding earnings expectations in previous quarters.

Market Reaction

The market reacted swiftly to the earnings miss, with Stepan’s stock price dropping by 8.8% to $55.24. This decline positions the stock closer to its 52-week low of $44.23, reflecting investor concerns over the company’s ability to meet future earnings targets amidst challenging market conditions. With a market capitalization of $1.14 billion and historically low price volatility (Beta: 1.0), InvestingPro analysis suggests the stock is currently undervalued. Get access to the comprehensive Pro Research Report, available for Stepan and 1,400+ other US stocks, to understand the full valuation picture.

Outlook & Guidance

Despite the Q2 earnings miss, Stepan remains optimistic about its full-year performance. The company expects to deliver growth in adjusted EBITDA and net income while aiming for positive free cash flow in 2025. Strategic initiatives include expanding product lines and optimizing assets to counteract raw material cost inflation. InvestingPro data shows current gross margins at 12.48%, highlighting the importance of these margin improvement initiatives. Two analysts have recently revised their earnings estimates upward for the upcoming period, suggesting potential improvement ahead.

Executive Commentary

CEO Luis Rojo emphasized, "We are planning to recover our margins gradually going forward," highlighting the company’s focus on margin improvement. He also stated, "Despite all the current market uncertainties, including the impact of tariffs, we remain optimistic that we will deliver full-year adjusted EBITDA and adjusted net income growth."

Risks and Challenges

• Rising raw material costs, such as coconut oil, could pressure margins.
• Lower demand in the commodity consumer products market may impact sales.
• High interest rates present a challenging macroeconomic environment.
• The impact of tariffs and geopolitical tensions could affect operations.
• The ongoing site expansions and product launches carry execution risks.

Q&A

During the earnings call, analysts inquired about the one-time impacts totaling $6 million, including the Pasadena startup and an EPA fine. Questions also focused on the company’s pricing strategies to offset raw material inflation and the potential sale of the Philippines site. These discussions underscored the company’s proactive measures to address current challenges.

Full transcript - Stepan Comp (SCL) Q2 2025:

Conference Call Operator: Good morning, and welcome to the Steppen Companies Second Quarter twenty twenty five Earnings Conference Call. During the presentation, all participants will be in a listen only mode. Afterward, we will conduct a question and answer session. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.

As a reminder, this call is being recorded on Wednesday, 07/30/2025. It is now my pleasure to turn the call over to Mr. Ruben Velasquez, Vice President and Chief Financial Officer of Stepan Company. Mr. Velasquez, please go ahead.

Ruben Velasquez, Vice President and Chief Financial Officer, Stepan Company: Good morning and thank you for joining Step and Company’s second quarter twenty twenty five financial review. Before we begin, please note that information in this conference call contains forward looking statements, which are not historical facts. These statements involve risks and uncertainties that could cause actual results to differ materially, including but not limited to prospects for our foreign operations, global and regional economic conditions, and factors detailed in our Securities and Exchange Commission filings. In addition, this conference call will include discussions of adjusted net income, adjusted EBITDA, and free cash flow, which are non GAAP measures. We provide reconciliations to the comparable GAAP measures in the earnings presentation and press release, which we have made available at www.stephan.com under the Investors section of our website.

Whether you are joining us online or over the phone, we encourage you to review the investor slide presentation. We make these slides available at approximately the same time as when the earnings release is issued. And we hope that you find the information and perspectives helpful. With that, I would like to turn the call over to Mr. Luis Rojo, our President and Chief Executive Officer.

Luis Rojo, President and Chief Executive Officer, Stepan Company: Thank you, Ruin. Good morning. And thank you all for joining us today to discuss our second quarter twenty twenty five results. Before we turn to business, I would like to welcome Ruben to his first Stepan conference earnings call. And I look forward to working together on our new journey of growth and transformation.

I also want to extend my sincere appreciation to Sam for his dedication, steady leadership and contributions to the interim period. Thank you, Sam. Moving on, I plan to share highlights of the quarterly performance and will also share updates on our key strategic priorities, while Ruben will provide additional details on our financial results. We delivered double digit adjusted EBITDA growth in the 2025. These results were restrained by the significant increase in all your chemicals raw material prices, which impacted surfactant margins.

We are planning to recover our margins gradually going forward. The company reported second quarter adjusted EBITDA of $51,400,000 up 8% versus the prior year. Polymers delivered double digit adjusted EBITDA growth. Surfactant adjusted EBITDA was similar to last year, driven by excellent growth in our crop productivity business, fully offset by significant raw material inflation. Specialty Product adjusted EBITDA was impacted by order timing changes, and the business continues to deliver solid growth.

Volume grew 1% with polymers up 7% and our NCT product line up 49%, while surfactants volume was down 1%. We continue to experience double digit volume growth within the crop productivity and oil field end markets, which was offset by lower demand within the global commodity consumer products end market. North America and European rigid polyols volume grew low single digits, while the commodity PA business continues to deliver a strong growth year over year. We believe that Regipollo growth in North America and Europe continues to be restrained by global macroeconomic uncertainties and the high interest rate environment. We remain encouraged by the volume growth across several of our key strategic end markets.

We finished the 2025 with $12,000,000 of adjusted net income, up 27% versus the prior year, driven by earnings growth in polymers and crop productivity, as well as a lower tax rate. Production of our new Pasadena, Texas site is ramping up and should provide incremental benefits in the second half of the year. During the 2025, the company paid $8,700,000 in dividends to shareholders. Our Board of Directors declared a quarterly cash dividend on a Stepan stock of $0.03 $85 per share, payable on 09/15/2025. Stepan has paid an increase in dividend for fifty seven consecutive years.

Rui will now share some details of our second quarter results.

Ruben Velasquez, Vice President and Chief Financial Officer, Stepan Company: Thank you, Luis. My comments will generally follow the slide presentation. Let’s just start with the slide four to recap the quarter. Second quarter twenty twenty five adjusted net income was $12,000,000 or $0.52 per diluted share versus $9,400,000 or 41¢ per diluted share for the second quarter of last year, a 27% increase. The increase was driven by earnings growth across polymers and productivity and a lower tax rate.

Significantly higher ole chemical raw material costs continue to be impacted margins. Earnings growth was also impacted by higher startup expenses at our new alkylation facility in Pasadena, Texas and environmental remediation reserve adjustment at our Millstone site and an EPA penalty. We believe that we will be able to recover the EPA penalty from third parties. Cash from operations was $11,200,000 for the quarter and free cash flow was negative at $14,400,000 due to inventory builds in anticipation of ferries and to provide safe stock in advance of the hurricane season and a new collective bargaining agreement in our Millesdale site. Slide five shows the total company net income bridge for the 2025 compared to last year’s second quarter and breaks down the increase in adjusted income.

Because this is net income, the figures noted are on an after tax basis. We will cover each segment in more detail. But to summarize, we delivered operating income growth in polymers, partially offset by lower operating results in surfactants and specialty products. The second quarter results benefited from a lower effective tax rate. The effective tax rate was 19.2% during the first half of the year versus our normal range of 24% to 26%.

This decrease was primarily driven by favorable discrete items associated with a tax audit settlement in The U. S. Slide six shows the total company adjusted EBITDA bridge for the second quarter compared to last year’s second quarter. Adjusted EBITDA was $51,400,000 versus $47,700,000 in the prior year, an 8% increase. We will cover each segment in more detail, but to summarize, we delivered adjusted EBITDA growth in global polymers, partially offset by specialty products and a slightly lower earnings in surfactants.

Adjusted EBITDA results also benefited from lower corporate expenses compared to previous year. Slide seven focuses on the surfactant segment results. Surfactant net sales were $411,500,000 for the quarter, an 8% increase versus prior year. Selling prices were up 11% primarily due to improved product and customer mix and the pass through of higher raw material costs. Sales volume declined one percent year over year due to lower demand within the global commodity consumer product end markets, partially offset by double digit growth within the agricultural and oilfield end markets.

Foreign currency translation negatively impacted net sales by 2%. SORTACAN’s adjusted EBITDA decreased $500,000 or one percent versus the prior year. This decrease was driven by the 1% contraction in sales volume, higher Pasadena site startup expenses, and the significant rise in all of chemical raw material prices, together with an increase to an environmental remediation reserve at our new site and an EPA fund. This was partially offset by improved product and customer mix. Moving to Slide eight, polymer net sales were $162,800,000 for the quarter, a 2% increase versus the prior year.

Selling prices decreased 7%, primarily due to the pass through of lower raw material costs and competitive pressures. Sales volume increased 7% in the quarter. North American and European region polyol volume grew low single digits despite the continued challenging overall environment. Specialty polyols was down low single digits and commodity, phthalate and hydrate volume delivered strong growth year over year. China polymers volume was down low double digits.

Foreign currency translation had a positive impact of 2% on net sales during the quarter. All of your adjusted EBITDA increased $3,800,000 or 17% versus the prior year, primarily due to 7% volume growth, which was partially offset by less favorable product mix. Finally, specialty product net sales were $20,500,000 for the quarter, a 22% increase versus the prior year, primarily due to higher sales volume. Specialty product adjusted EBITDA decreased $2,100,000 or 24 percent. The decrease in adjusted EBITDA was primarily due to order timing fluctuations within the pharmaceutical business as orders were moved from the second quarter to the second half of the year.

Next on the slide nine, free cash flow was negative at $14,400,000 for the second quarter, down $14,200,000 year over year reflecting both higher working capital requirements as well as increased purchases of raw materials in anticipation of tariffs and to support business growth. We are optimistic in our ability to deliver positive free cash flow for the full year 2025. During the second quarter, we deployed $25,600,000 against capital investments and $8,700,000 for dividends. Now on Slide ten and eleven, Luis will update you on our strategic priorities and capital investments.

Luis Rojo, President and Chief Executive Officer, Stepan Company: Thanks, Ruben. Our customers will always remain at the center of our strategy and innovation efforts. Our Tier one customer base remain a solid foundation of our business. Continue our new customer acquisition within Tier two and Tier three customer remains a key priority. This is an important and profitable growth channel within our Surfactant business.

For the 2025, our volume grew low single digits year over year, and we added over 400 new customers. Our end market diversification strategy remains a key focus area. For the second quarter, we continue to see double digit growth in our crop productivity and oilfield businesses. We are pleased to see our North American and European rigid polyol business continues to deliver year over year growth. Insulation remains a critical enabler of a more sustainable and energy efficient world, and we are confident in the long term growth prospect of this business.

Our focus continues to be on developing the next generation really polytechnologies that can increase the energy efficiency and cost performance of our customer insulation products. Additionally, we’re excited about the new products we’re introducing in the growing spray foam end market. Within polymers, we’re able to achieve significant growth in our commodity PA business, which will enable us to deliver earnings growth in 2025. Our supply chain operation and resiliency continues to improve and we delivered another solid quarter in all our key operational metrics. We continue making investments in our Neotel site to improve operational reliability.

Moving to Slide 11, we continue to ramp up production of our new PASALINATEXA sites. We have made 31 different products to date. We expect that the full contribution rate of the plant will be achieved during the 2025 with full year benefit in 2026. Our commercial team continues to develop and deliver new business opportunities and especially epoxylation volumes continues to grow strong double digits in the second quarter. Looking forward, we remain focused on accelerating our business’ strategy through enhanced operational excellence to grow volume, improve product and customer mix and accelerate free cash flow generation.

We believe our Surfactant business will experience continued growth in our key strategic end markets and that polymers demand will continue improving as we get more market certainty and we execute our innovation and growth plans. Our Pasadena facility is operational and as we have previously communicated, this should enable us to deliver volume growth in our glycosylation product line and supply chain savings going forward. We remain on track to close the sale of our site in The Philippines in the 2025. And we will continue to look for opportunities to optimize our footprint and asset base around the world. Despite all the current market uncertainties, including the impact of tariffs, we remain optimistic that we will deliver full year adjusted EBITDA and adjusted net income growth and positive free cash flow in 2025.

This concludes our prepared remarks. At this time, we would like to turn the call over for questions. Gigi, please review the instruction for the questions portions of today’s call.

Conference Call Operator: Thank you. As a reminder, to ask a question, please press star, 11 on your telephone, and wait for your name to be announced. Our first question comes from the line of Mike Harrison from Seaport Research Partners.

Mike Harrison, Analyst, Seaport Research Partners: Hi, good morning.

Luis Rojo, President and Chief Executive Officer, Stepan Company: Good morning, Mike.

Mike Harrison, Analyst, Seaport Research Partners: Wanted to say congratulations and welcome to Ruben. Know, first question I have is, it sounds like there were some one time impacts in the Surfactants business. You mentioned the Pasadena startup costs. I believe you quantified that at about 6,000,000 but was hoping you could quantify the remediation reserve adjustment, the EPA penalty, and I guess any other one time or unusual impacts. And then the next question is going to be on raw materials.

So let’s save the raw material discussion for a minute.

Luis Rojo, President and Chief Executive Officer, Stepan Company: Thanks, Mike. The $6,000,000 includes all the one diners that we have. So, includes Pasadena, includes the EPA fine, which we are planning to recover. The EPA fine is around a million, and we’re planning to recover that in the next few quarters. But the majority of the impact was the mill cell reserve for environmental remediation work and also the start up of Pasadena.

So, all of those three items is the $6,000,000

Mike Harrison, Analyst, Seaport Research Partners: All right, perfect. And then in terms of the raw material impact, can you just give us a little bit more color on what you’re seeing in terms of the timing? I guess, if there’s any way to help quantify the headwind that you saw in Q2 and also the timing of getting pricing to offset those higher raw material costs. Presumably, you expect to catch back up in the second half, but any greater detail on how that quarterly cadence goes would be helpful.

Luis Rojo, President and Chief Executive Officer, Stepan Company: Yes, great question, Mike. And let me start with the first half of the year was a decent year. I’m not happy with the first half. It could have been better, but it could have been significantly worse if you think about where the chemical industry is. But if you think of the first half, we are growing adjusted EBITDA in surfactants, in polymers, and specialty products is only a timing thing.

We shipped a lot of the pharma business last Q2 in 2024, and we are going to ship it now in the 2025. So, if you exclude that, we are growing adjusted EBITDA in the three businesses that we have, which is remarkable and it’s a good base to start with. Now, let’s go deeper into Surfactants because that’s where your question was. And if you think about the $83,000,000 of adjusted EBITDA in the first half for Surfactants, of course, we’re not happy with 83,000,000 and five percent growth. But if you think about the one timers that we had as we were talking, you know, all the start up of Pasadena and Millville and the EPA, plus the raw material situation, 5% growth is a decent number.

What I would tell you is when you think about the raw material impact, see coconut oil at $3,000 per metric ton, which used to be $1,000 per metric ton eighteen months ago. We are still catching up on our price execution. We had, everybody knows we had another price execution at the end of the quarter in June. So that of course is not reflected in the quarter. So the true norm that I see instead of that $83,000,000 that you saw for the first half in adjusted net income, I see 90,000,093 million dollars right?

That’s where the surfactant business should be. And of course, from that 90 plus, that our challenge now is how we’re going to grow from that 90 plus with Pasadena savings, with the pricing kicking in and all of that. So, feel good about what the team is delivering. There are lacks and we cannot execute and we cannot recover everything overnight. But I feel good about the trajectory that we had in the first half.

And I think what we executed and what we are executing in the next few quarters with productivity, with pricing, with Pasadena will allow this business to get where their EBITDA needs to be. And you know, we don’t provide guidance, but you can see that I’m telling you 90 plus should be the number in the first half. And on top of that, we need to deliver more pricing on Pasadena savings.

Mike Harrison, Analyst, Seaport Research Partners: All right. That’s very helpful. I guess last question for me is you mentioned the new collective bargaining agreement in Millsdale. What are the effects of that? Is that more of a comment on Q2 performance or is that a future impact related to presumably higher wages and benefits?

Luis Rojo, President and Chief Executive Officer, Stepan Company: Well, look, we’re extremely happy with our workforce in Millville. And this is an event that happens every four years. So the previous agreement was done in 2021. And we just executed the new agreement for the next four years. We’re extremely happy with our workforce in Millville, and we will continue improving their productivity and all the efforts that we’re The plant is running better than previous years, but we still need to make improvements.

And we make a comment because, of course, we always build inventory as part of that process. So that is kind of a cash impact in our inventories.

Mike Harrison, Analyst, Seaport Research Partners: All right, understood. Thanks very much.

Conference Call Operator: Thank you. One moment for our next question. Our next question comes from the line of Dave Storms from Stonegate.

Dave Storms, Analyst, Stonegate: Hey, good morning.

Luis Rojo, President and Chief Executive Officer, Stepan Company: Good morning, Good

Dave Storms, Analyst, Stonegate: Good morning. I want to start with the AOS expansion that you announced mid quarter. And I want to kind of get your thoughts on maybe who stands to benefit the most

Ruben Velasquez, Vice President and Chief Financial Officer, Stepan Company: from this. Is this

Dave Storms, Analyst, Stonegate: targeted at training capacity for tier one clients, tier two or three clients? What would you share the long term benefits from this?

Luis Rojo, President and Chief Executive Officer, Stepan Company: Great question, Dave. I’m happy that you bring this topic up because we have talked a lot in the past about low 14 and sulfate. The reality is we want to make sure that Stefan is a one stop shop. We have all the technologies that you need in Surfactants to deliver the products that you want to deliver in the marketplace. AUS is an important building block for the sulfate free business.

We want to be more aggressive in the sulfate free business in the future because it’s an important growth element of the market. If you think about a lot of the beauty care industry continues, this is a trend that I started many, many years ago and continues to be like that, is going through a lot of sulfate free technology. So, we want to make sure that we offer all the options when you think about surfactants and when you think about feedstocks to our customers to get to the best performance and cost for what they need. AOS is an important building block. We have extra capacity and we’re going to grow in AOS in the near future for sure.

Dave Storms, Analyst, Stonegate: Understood. That’s very helpful. Thank you. And then just kind of switching gears, thinking about The Philippines asset sale that you mentioned is expected to close in 4Q. You also mentioned that you’re continuing to look at other asset optimization opportunities.

Just any sense of what those opportunities would look like? Any other levers you’re going to looking at pulling? Would it take the form of more asset sales or do you have other things in mind?

Luis Rojo, President and Chief Executive Officer, Stepan Company: Great question, Dave. And we will continue looking at our footprint. We will continue to look at all our assets even within plans. We are looking at the productivity of each of our assets because we need to make sure that we get the return that we deserve from each of those assets. So there is no secret that there is overcapacity in the chemical industry overall.

I’m not talking about Estepa, but overall there is extra capacity, and that’s where the whole industry needs to be more careful on making sure that we rationalize that capacity. In our case, we’re looking at several options, and we will continue optimizing our asset base going forward. Nothing concrete right now, but you will hear more from us in the future.

Dave Storms, Analyst, Stonegate: That’s very helpful. Thank you. One more, if I could sneak it in, and apologies if I missed this in the prepared remarks. The tax benefit that you saw in the quarter, that’s expected to be a one time benefit and tax rates going forward should return to the normal range?

Luis Rojo, President and Chief Executive Officer, Stepan Company: Yeah, you’re totally right. We had a few IRS audit closures that provided benefits to us, discrete benefits. So we continue to believe that our normal tax rate is between 24% to 26% and that’s the normal going rate. Of course, we will continue working on projects. If, so, but the normal going rate will continue to be the 24%, 26% effective tax rate.

Dave Storms, Analyst, Stonegate: Understood. Thank you for taking my questions and good luck in the next quarter.

Luis Rojo, President and Chief Executive Officer, Stepan Company: Thank you.

Conference Call Operator: Thank you. As a reminder to ask a question, please press 11 At this time, I would now like to turn the conference back over to Luis Rojo for closing remarks.

Luis Rojo, President and Chief Executive Officer, Stepan Company: Thank you very much for joining us on today’s call. We appreciate your interest and ownership in Stepan Company. Have a great day.

Conference Call Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.